Abstract:Background and Aims: Hepatocellular carcinoma (HCC) is one of the most common malignancies in the world. A recent randomized phase III trial of combined immunotherapy (atezolizumab) with antiangiogenesis (bevacizumab) versus the standard sorafenib monotherapy reported an unprecedented response rate of 27%, leading to FDA approval of this combination as the new standard treatment in May 2020. Yet, despite this undisputable progress, the majority of the HCC cases are likely to recur or develop resistance to both first line therapy. In this study, we aimed to identify novel, druggable candidate genes for patients with sorafenib resistant HCC. Method: CRISPR/Cas9 genome (GeCKO v2) library screening was used to identify loss of function mutations conferring sorafenib resistance upon HCC cells. CCK-8 and clonogenic assays were used to measure cell viability and cytotoxicity. Flow cytometry was performed to analyze cellular reactive oxidative species (ROS) and apoptosis level. Multiple animal models were used to study the synergistic efficacy of the combination of nuclear factor erythroid 2- related factor 2 (NRF2) inhibition and sorafenib. Results: In our study, we explored the mechanisms underlying sensitivity of HCC cells to sorafenib using genome-wide CRISPR-Cas9 screening. Kelch-like ECH- associated protein-1(KAEP1) was discovered as a previously unknown factor for determining the sensitivity of HCC cells to sorafenib. Using established sorafenib resistant HCC cell lines and the parental cell, we validated that KEAP1 mediates NRF2 degradation through the ubiquitin-proteasome pathway, thereby conferring sensitivity to sorafenib. Conversely, the loss of function of KEAP1 reduced degradation of NRF2 and conferred increased sorafenib resistance. Analysis of 55 patients with HCC, who had received hepatic resection followed by postoperative standard sorafenib treatment, revealed that high NRF2 expression shortened both overall survival (P<0.05) and disease free survival (P<0.01). CCK-8 and clonogenic assays were used in combination with sorafenib revealed that NRF2 inhibitor substantially enhances cytotoxicity and leads to robust proliferation inhibition of sorafenib resistant HCC cells, as compared with single agents. In both cell derived xenograft (CDX) and patient-derived xenograft (PDX) HCC models with preserved NRF2 function, NRF2 inhibitor, in combination with sorafenib, showed significant antitumor activity (P<0.05). Furthermore, the combination of NRF2 inhibitor and sorafenib shows striking synergy by increasing ROS and inducing apoptosis in HCC cells. Conclusion: Our results uncovered the potential of NRF2 as a drug target for patients with sorafenib resistant HCC. The impressive efficacy of NRF2 inhibitor and sorafenib suggests a potential combination therapy to supplement the existing standard of treatment for sorafenib resistant HCC. Citation Format: Jiang Chen, Shi Jiang, Bixia Li, Tong Ji, Staiculescu Daniel, Jiayan He, Junjie Xu, Xiujun Cai. Small molecule inhibitor of NRF2 selectively overcomes sorafenib resistance in KEAP1-deficient hepatocellular carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1419.

Knockdown of AKR1C3 Promoted Sorafenib Sensitivity Through Inhibiting the Phosphorylation of AKT in Hepatocellular Carcinoma

Integrating Bulk-Rna and Single-Cell Analysis Reveals Heterogeneous Expression of Cuproptosis-Related Sorafenib-Resistant Genes in Hepatocellular Carcinoma

Abstract A155: Activation of PI3K/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells

Activation of Phosphatidylinositol 3-Kinase/akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells

AKR1C3 suppresses ferroptosis in hepatocellular carcinoma through regulation of YAP/SLC7A11 signaling pathway

Increasing AR by HIF-2α Inhibitor (PT-2385) Overcomes the Side-Effects of Sorafenib by Suppressing Hepatocellular Carcinoma Invasion Via Alteration of Pstat3, Pakt and Perk Signals

AKR1C3-dependent lipid droplet formation confers hepatocellular carcinoma cell adaptability to targeted therapy

The Mir-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis Through Altering the Androgen Receptor Signals

Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint.

CCT3 drives Sorafenib resistance by inhibiting TFRC-mediated iron uptake in HCC

KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma Via TWIST Regulated Epithelial-Mesenchymal Transition.

AKR1B10 Inhibitor Epalrestat Facilitates Sorafenib-Induced Apoptosis and Autophagy Via Targeting the mTOR Pathway in Hepatocellular Carcinoma

CCT3/ACTN4/TFRC axis protects hepatocellular carcinoma cells from ferroptosis by inhibiting iron endocytosis

Abstract 1419: Small Molecule Inhibitor of NRF2 Selectively Overcomes Sorafenib Resistance in KEAP1-deficient Hepatocellular Carcinoma

Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma

AKR1C1 overexpression leads to lenvatinib resistance in hepatocellular carcinoma

Activation Of Phosphatidylinositol 3-Kinase/Akt/Snail Signaling Pathway Contributes To Epithelial-Mesenchymal Transition-Induced Multi-Drug Resistance To Sorafenib In Hepatocellular Carcinoma Cells

AKR1C3 regulated by NRF2/MAFG complex promotes proliferation via stabilizing PARP1 in hepatocellular carcinoma

Sorafenib modulates the gene expression of multi-drug resistance mediating ATP-binding cassette proteins in experimental hepatocellular carcinoma.

LINC00540 Promotes Sorafenib Resistance and Functions As a Cerna for Mir-4677-3p to Regulate AKR1C2 in Hepatocellular Carcinoma

[AKR1B10 inhibitor enhances the inhibitory effect of sorafenib on liver cancer xenograft].